A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

1. Male or female subjects aged ≥18 years old.

2. Subjects diagnosed with moderate to severe plaque psoriasis with or withoutpsoriatic arthritis.

3. At screening and baseline, PASI score ≥ 12 , Body Surface Area(BSA) ≥ 10%, sPGA ≥ 3.

4. Suitable for systematic therapy assessed by investigators.

5. Subjects who are women of childbearing potential must have a negative pregnancy testat screening and must be practicing an adequate, medically acceptable method ofbirth control during the study and for at least 6 months after the last study drugadministration.

Exclusion Criteria:

1. Types of psoriasis other than chronic plaque-type psoriasis.

2. Drug-induced psoriasis.

3. Evidence of active TB. Patients with evidence of latent tuberculosis may enter thetrial after sufficient treatment had initiated and maintained according to protocol.

4. Positive results of confirmatory test for hepatitis B, hepatitis C, humanimmunodeficiency virus (HIV) or syphilis.

5. History of repeated chronic infection, had any serious infection or systemicinfection within 2 months before screening.

6. Progressive or uncontrolled symptoms or signs of circulatory, respiratory,digestive, neuropsychiatric or psychological, hematological, endocrine and othersystems before randomization.

7. History of malignant tumour within 5 years before screening.

8. Previous or current autoimmune diseases.

9. Allergic to any component of the investigational drug, or have had severe allergicreactions to monoclonal antibodies.